Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The PERSEVERE Study
Recruiting
RCT of High-Risk Pulmonary Embolism Comparing FlowTriever System vs. Standard of Care
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: HCA Medical City Heart & Spine, Dallas, Texas
Conditions: Pulmonary Embolism, Pulmonary Thromboembolism
Heat and Exercise in Aging as Therapy (HEAT)
Recruiting
The main goal of this two-phase clinical trial is to learn whether local heat therapy, using heat pads applied to the legs, can enhance skeletal muscle health, physical function, and blood sugar control in a manner comparable to exercise, specifically High-Intensity Interval Training (HIIT), in older individuals with prediabetes. The study aims to answer the following questions: 1. Does local heat therapy improve muscle architecture (e.g., muscle cross-sectional area, capillary density, mitocho... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/11/2025
Locations: Texas Tech University, Lubbock, Texas
Conditions: Prediabetic State
Effect of Transcutaneous Electrical Nerve Stimulation on Post-stroke Patients
Recruiting
The subjects will be asked to attend minimum 15 separate sessions, 6 for testing changes in reflex behaviors, 3 for testing changes in the influence of descending motor tracts on spinal motor neurons, 3 for each testing functional movement in response to a trip event and cross-tilt walking adaptation pattern, as part of their participation in the research study. The estimated amount of time to enroll and collect the data for each of the subjects is four months' time. The data will be analyzed an... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/11/2025
Locations: University of Texas Medical Center, Dallas, Texas
Conditions: Hemiplegia and/or Hemiparesis Following Stroke, Anterior Circulation Stroke of Uncertain Pathology
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
Recruiting
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Lymphocytic Leukemia
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Recruiting
Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Mantle Cell Lymphoma
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Recruiting
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the sa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2025
Locations: Central Texas Clinical Research, LLC, Austin, Texas
Conditions: Moderately to Severely Active Crohn Disease
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Recruiting
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Alina Clinical Trials, Dallas, Texas
Conditions: Chronic Spontaneous Urticaria
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
Recruiting
To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Bladder Cancer
The Use of Karl Storz Curved Fetoscope (11508aak) and Its Straight Version (11506akk) for In-utero Surgery
Recruiting
The purpose of this study is to prospectively evaluate the efficacy of KARL STORZ curved fetoscope (11508AAK) and its straight version (11506AAK) for in-utero surgery
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
08/11/2025
Locations: The University of Texas health Science Center at Houston, Houston, Texas
Conditions: In Utero Procedure Affecting Fetus or Newborn
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Recruiting
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/11/2025
Locations: UT Southwestern, Dallas, Texas
Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Study Evaluating APG777 in Atopic Dermatitis
Recruiting
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants ra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Investigational Site, Dallas, Texas
Conditions: Atopic Dermatitis
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
Recruiting
This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP. The study will be conducted at a single study center. In this study, 2 cohorts (N=24, 12 subjects for each cohort), each cohort will consist of 10 active and 2 placebo, with approximately equal numbers of male and female subjects. Each su... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/11/2025
Locations: Clinical Trials of Texas,LLC, Fredericksburg, Texas
Conditions: Diabetic Peripheral Neuropathic Pain